Date: 2014-04-22
Type of information: Grant
Company: Hoopika Biotech (Austria)
Investors: Austrian Research Promotion Agency (FFG) (Austria)
Amount: € 1.64 million + € 3.38 million
Funding type: grant
Planned used: The grant will support the development of HB101, a vaccine against a persistent viral infection in humans. Hookipa Biotech is focused on the development of innovative prophylactic and therapeutic vaccines based on its proprietary Vaxwave® technology. The vaccine platform is using a replication-defective viral vector for the prevention and treatment of multiple infectious diseases and cancer. It has been validated in various disease models.
Others: * On April 22, 2014, Hookipa Biotech announced the award of a major grant from the Austrian Research Promotion Agency (Forschungs-Förderungs-Gesellschaft, FFG). A €3.38 million support is given for the second year of a multi-year vaccine development project. * On September 18, 2012, Hookipa Biotech announced the award of a grant from the Austrian Research Promotion Agency (Forschungs-Förderungs-Gesellschaft, FFG), the leading public funding agency for translational research in Austria. The support from FFG for the first year amounts to € 1.64 million; additional funding of up to 70% of the total project costs is expected in the next three years.
Therapeutic area: Cancer - Oncology - Infectious diseases
